Loading...
12/16 05:28
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: stable revenue with signs of recovery but increased costs leading to a loss. The data business shows potential growth, but management's vague responses in the Q&A about future opportunities and revenue guidance create uncertainty. Operational inefficiencies and increased expenses further complicate the outlook. Despite optimism in some areas, the lack of clear guidance and current financial strain suggest a neutral stock movement in the short term.
Revenue $14 million in Q1 fiscal 2026, flat year-over-year but a rebound from $12.4 million in Q4 fiscal 2025. The rebound was attributed to growth in the TOS business and contributions from the emerging data platform.
Research Services Revenue $13.7 million in Q1 fiscal 2026, contributing the majority of the total revenue.
Data Business Revenue Balance of the $14 million total revenue in Q1 fiscal 2026, showing growth as it generated sales for three consecutive quarters.
Loss from Operations (GAAP) $0.5 million in Q1 fiscal 2026 compared to income from operations of $1.3 million in Q1 fiscal 2025. The loss included $600,000 in noncash expenses such as stock-based compensation and depreciation.
Adjusted EBITDA $60,000 in Q1 fiscal 2026, down from $2 million in Q1 fiscal 2025. The decline was due to increased costs and investments in R&D and sales and marketing.
Gross Margin 43% in Q1 fiscal 2026, down from 50% in Q1 fiscal 2025. The decline was primarily due to increased outsourced lab service costs for radio labeling work, which is expected to improve as the work is brought in-house.
Operating Expenses $6 million in Q1 fiscal 2026, up $1 million year-over-year. The increase was driven by $0.6 million in R&D, $0.2 million in sales and marketing, and $0.2 million in G&A expenses.
Cash Position $10.3 million at the end of Q1 fiscal 2026, up $0.5 million from year-end. The company remains debt-free and had positive operating cash flow of $0.6 million.
Radiopharmaceutical services platform: Expanded radioactive materials license, new radiochemistry infrastructure, and over 30 screened PDX models enable fully integrated workflows from biodistribution to efficacy testing on clinically relevant tumor models.
Data platform: Generated data sales for 3 consecutive quarters, leveraging a uniquely characterized PDX bank to create a comprehensive and clinically relevant tumor data set.
Corellia drug discovery subsidiary: Continues to advance with compelling data from platform and in vivo experiments, despite funding headwinds in biotech.
TOS business: Growth led by TOS business with contributions from the emerging data platform, supported by improving trends in biotech funding and R&D budgets.
Large pharma relationships: Growing relationships with large pharma creating opportunities for larger, more durable bookings.
Revenue: Achieved $14 million in Q1 revenue, rebounding from $12.4 million in Q4.
Gross margin: Declined to 43% from 50% in Q1 last year due to increased outsourced lab service costs for radio labeling work, with expectations of margin expansion as work is brought in-house.
Operating expenses: Increased by $1 million year-over-year, driven by R&D, sales and marketing, and IT costs.
Cash position: Ended Q1 with $10.3 million in cash, up $0.5 million from year-end, and remained debt-free.
Radiopharma and data initiatives: Advanced strategic initiatives in radiopharma and data, reinforcing the foundation for long-term success.
Cost management: Focused on disciplined cost management and streamlining system inefficiencies to support growth.
Biotech Funding and R&D Budget Pressures: The macro environment remains challenging with biotech funding and R&D budgets still under pressure, which could impact customer spending and growth opportunities.
Customer Cancellations and Revenue Conversion: Although improving, customer cancellations and bookings to revenue conversion remain areas of concern, potentially affecting revenue stability.
Gross Margin Decline: Gross margin declined from 50% to 43% year-over-year, primarily due to increased outsourced lab service costs for radio labeling work. This could impact profitability until the work is brought in-house.
Operating Loss: The company recorded a GAAP operating loss of $0.5 million compared to income from operations of $1.3 million in the same quarter last year, indicating financial pressure.
Increased Operating Expenses: Operating expenses rose by $1 million year-over-year, driven by higher R&D, sales and marketing, and G&A costs. While some increases are strategic, they could strain financials if not managed effectively.
System Inefficiencies: Temporary increases in G&A costs are attributed to system inefficiencies, which could hinder operational efficiency and increase costs if not resolved.
Revenue Growth: The company expects sequential revenue growth in the upcoming quarters of fiscal 2026, building on the $14 million reported in Q1.
Profitability: Champions Oncology anticipates continued profitability on an adjusted EBITDA basis in the near term.
Margin Expansion: Gross margins are expected to expand as radio labeling work is brought in-house, reducing outsourced lab service costs.
Cash Flow: The company projects to remain roughly cash neutral in Q2 and expects cash growth in the second half of fiscal 2026 as revenues increase and margins expand.
Data Business Growth: Investments in the data business are expected to support growth in the coming quarters, leveraging the company's uniquely characterized PDX bank and the increasing role of AI and machine learning in drug discovery.
Radiopharmaceutical Services: The company is expanding its radiopharmaceutical services platform, which is expected to reduce costs, improve gross margins, and offer fully integrated workflows in a fast-growing field.
Corellia Drug Discovery: Corellia, the company's drug discovery subsidiary, is expected to translate its compelling data and in vivo experiments into meaningful investment opportunities despite funding headwinds in biotech.
The selected topic was not discussed during the call.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
